{
  "DOI": "10.1007/s00439-010-0900-x",
  "ISSN": [
    "0340-6717",
    "1432-1203"
  ],
  "URL": "http://dx.doi.org/10.1007/s00439-010-0900-x",
  "alternative-id": [
    "900"
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Mizuarai",
      "given": "Shinji",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Kotani",
      "given": "Hidehito",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": []
  },
  "created": {
    "date-parts": [
      [
        2010,
        10,
        25
      ]
    ],
    "date-time": "2010-10-25T09:07:50Z",
    "timestamp": 1287997670000
  },
  "deposited": {
    "date-parts": [
      [
        2019,
        6,
        5
      ]
    ],
    "date-time": "2019-06-05T21:15:10Z",
    "timestamp": 1559769310000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        1,
        15
      ]
    ],
    "date-time": "2024-01-15T23:57:04Z",
    "timestamp": 1705363024911
  },
  "is-referenced-by-count": 11,
  "issn-type": [
    {
      "type": "print",
      "value": "0340-6717"
    },
    {
      "type": "electronic",
      "value": "1432-1203"
    }
  ],
  "issue": "6",
  "issued": {
    "date-parts": [
      [
        2010,
        10,
        26
      ]
    ]
  },
  "journal-issue": {
    "issue": "6",
    "published-print": {
      "date-parts": [
        [
          2010,
          12
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "http://www.springer.com/tdm",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2010,
            10,
            26
          ]
        ],
        "date-time": "2010-10-26T00:00:00Z",
        "timestamp": 1288051200000
      }
    }
  ],
  "link": [
    {
      "URL": "http://link.springer.com/content/pdf/10.1007/s00439-010-0900-x.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/article/10.1007/s00439-010-0900-x/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://link.springer.com/content/pdf/10.1007/s00439-010-0900-x",
      "content-type": "unspecified",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "567-575",
  "prefix": "10.1007",
  "published": {
    "date-parts": [
      [
        2010,
        10,
        26
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2010,
        10,
        26
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2010,
        12
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1016/S0140-6736(10)60893-8",
      "author": "MW Audeh",
      "doi-asserted-by": "crossref",
      "first-page": "245",
      "journal-title": "Lancet",
      "key": "900_CR1",
      "unstructured": "Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245–251",
      "volume": "376",
      "year": "2010"
    },
    {
      "DOI": "10.1073/pnas.1007462107",
      "author": "A Baldwin",
      "doi-asserted-by": "crossref",
      "first-page": "12463",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "900_CR2",
      "unstructured": "Baldwin A, Grueneberg DA, Hellner K, Sawyer J, Grace M, Li W, Harlow E, Munger K (2010) Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. Proc Natl Acad Sci USA 107:12463–12468",
      "volume": "107",
      "year": "2010"
    },
    {
      "DOI": "10.1200/jco.2010.28.18_suppl.3",
      "doi-asserted-by": "crossref",
      "key": "900_CR3",
      "unstructured": "Bang Y, Kwak EL, Shaw AT, Camidge DR, Iafrate AJ, Maki RG, Solomon BJ, Ou SI, Salgia R and Clark JW (2010) Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28:18s (suppl; abstr 3)"
    },
    {
      "DOI": "10.1038/nature08460",
      "author": "DA Barbie",
      "doi-asserted-by": "crossref",
      "first-page": "108",
      "journal-title": "Nature",
      "key": "900_CR4",
      "unstructured": "Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108–112",
      "volume": "462",
      "year": "2009"
    },
    {
      "DOI": "10.1128/MCB.01229-06",
      "author": "SR Bartz",
      "doi-asserted-by": "crossref",
      "first-page": "9377",
      "journal-title": "Mol Cell Biol",
      "key": "900_CR5",
      "unstructured": "Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, Needham R, Guo J, Gordon M, Chung N, Warrener P, Jackson AL, Carleton M, Oatley M, Locco L, Santini F, Smith T, Kunapuli P, Ferrer M, Strulovici B, Friend SH, Linsley PS (2006) Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 26:9377–9386",
      "volume": "26",
      "year": "2006"
    },
    {
      "DOI": "10.1038/nmeth.1330",
      "author": "MC Bassik",
      "doi-asserted-by": "crossref",
      "first-page": "443",
      "journal-title": "Nat Methods",
      "key": "900_CR6",
      "unstructured": "Bassik MC, Lebbink RJ, Churchman LS, Ingolia NT, Patena W, LeProust EM, Schuldiner M, Weissman JS, McManus MT (2009) Rapid creation and quantitative monitoring of high coverage shRNA libraries. Nat Methods 6:443–445",
      "volume": "6",
      "year": "2009"
    },
    {
      "DOI": "10.1038/nature02371",
      "author": "K Berns",
      "doi-asserted-by": "crossref",
      "first-page": "431",
      "journal-title": "Nature",
      "key": "900_CR7",
      "unstructured": "Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, Agami R, Ge W, Cavet G, Linsley PS, Beijersbergen RL, Bernards R (2004) A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428:431–437",
      "volume": "428",
      "year": "2004"
    },
    {
      "DOI": "10.1073/pnas.0806574105",
      "author": "A Bommi-Reddy",
      "doi-asserted-by": "crossref",
      "first-page": "16484",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "900_CR8",
      "unstructured": "Bommi-Reddy A, Almeciga I, Sawyer J, Geisen C, Li W, Harlow E, Kaelin WG Jr, Grueneberg DA (2008) Kinase requirements in human cells: III. Altered kinase requirements in VHL−/− cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA 105:16484–16489",
      "volume": "105",
      "year": "2008"
    },
    {
      "DOI": "10.1038/nrc2693",
      "author": "R Brosh",
      "doi-asserted-by": "crossref",
      "first-page": "701",
      "journal-title": "Nat Rev Cancer",
      "key": "900_CR9",
      "unstructured": "Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9:701–713",
      "volume": "9",
      "year": "2009"
    },
    {
      "DOI": "10.1038/nature03443",
      "author": "HE Bryant",
      "doi-asserted-by": "crossref",
      "first-page": "913",
      "journal-title": "Nature",
      "key": "900_CR10",
      "unstructured": "Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917",
      "volume": "434",
      "year": "2005"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-06-1986",
      "author": "D Cho",
      "doi-asserted-by": "crossref",
      "first-page": "758s",
      "issue": "2Pt2",
      "journal-title": "Clin Cancer Res",
      "key": "900_CR11",
      "unstructured": "Cho D, Signoretti S, Regan M, Mier JW, Atkins MB (2007) The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 13(2Pt2):758s–763s",
      "volume": "13",
      "year": "2007"
    },
    {
      "DOI": "10.1038/sj.onc.1203283",
      "author": "GK Dasika",
      "doi-asserted-by": "crossref",
      "first-page": "7883",
      "journal-title": "Oncogene",
      "key": "900_CR12",
      "unstructured": "Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, Lee EY (1999) DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18:7883–7899",
      "volume": "18",
      "year": "1999"
    },
    {
      "DOI": "10.1056/NEJM200104053441401",
      "author": "BJ Druker",
      "doi-asserted-by": "crossref",
      "first-page": "1031",
      "journal-title": "N Engl J Med",
      "key": "900_CR13",
      "unstructured": "Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037",
      "volume": "344",
      "year": "2001"
    },
    {
      "DOI": "10.1038/sj.onc.1209810",
      "author": "T Eguchi",
      "doi-asserted-by": "crossref",
      "first-page": "509",
      "journal-title": "Oncogene",
      "key": "900_CR14",
      "unstructured": "Eguchi T, Takaki T, Itadani H, Kotani H (2007) RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene. Oncogene 26:509–520",
      "volume": "26",
      "year": "2007"
    },
    {
      "DOI": "10.1158/1535-7163.MCT-08-1159",
      "author": "T Eguchi",
      "doi-asserted-by": "crossref",
      "first-page": "1460",
      "journal-title": "Mol Cancer Ther",
      "key": "900_CR15",
      "unstructured": "Eguchi T, Itadani H, Shimomura T, Kawanishi N, Hirai H, Kotani H (2009) Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines. Mol Cancer Ther 8:1460–1472",
      "volume": "8",
      "year": "2009"
    },
    {
      "DOI": "10.1038/nature03445",
      "author": "H Farmer",
      "doi-asserted-by": "crossref",
      "first-page": "917",
      "journal-title": "Nature",
      "key": "900_CR16",
      "unstructured": "Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921",
      "volume": "434",
      "year": "2005"
    },
    {
      "DOI": "10.1016/j.ejca.2010.07.031",
      "doi-asserted-by": "crossref",
      "key": "900_CR17",
      "unstructured": "Ferrari E, Lucca C, Foiani M (2010) A lethal combination for cancer cells: synthetic lethality screenings for drug discovery. Eur J Cancer [Epub ahead of print]"
    },
    {
      "DOI": "10.1056/NEJMoa0900212",
      "author": "PC Fong",
      "doi-asserted-by": "crossref",
      "first-page": "123",
      "journal-title": "N Engl J Med",
      "key": "900_CR18",
      "unstructured": "Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123–134",
      "volume": "361",
      "year": "2009"
    },
    {
      "DOI": "10.1128/MCB.18.7.3735",
      "author": "MW Frazier",
      "doi-asserted-by": "crossref",
      "first-page": "3735",
      "journal-title": "Mol Cell Biol",
      "key": "900_CR19",
      "unstructured": "Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP (1998) Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol 18:3735–3743",
      "volume": "18",
      "year": "1998"
    },
    {
      "DOI": "10.1158/1535-7163.MCT-10-0037",
      "author": "EB Garon",
      "doi-asserted-by": "crossref",
      "first-page": "1985",
      "journal-title": "Mol Cancer Ther",
      "key": "900_CR20",
      "unstructured": "Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, Kamranpour N, Pitts S, Desai A, Elashoff D, French T, Smith P, Slamon DJ (2010) Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther 9:1985–1994",
      "volume": "9",
      "year": "2010"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-04-0863",
      "author": "JI Geller",
      "doi-asserted-by": "crossref",
      "first-page": "6296",
      "journal-title": "Cancer Res",
      "key": "900_CR21",
      "unstructured": "Geller JI, Szekely-Szucs K, Petak I, Doyle B, Houghton JA (2004) P21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells. Cancer Res 64:6296–6303",
      "volume": "64",
      "year": "2004"
    },
    {
      "DOI": "10.1038/sj.onc.1207752",
      "author": "F Guo",
      "doi-asserted-by": "crossref",
      "first-page": "5577",
      "journal-title": "Oncogene",
      "key": "900_CR22",
      "unstructured": "Guo F, Zheng Y (2004) Rho family GTPases cooperate with p53 deletion to promote primary mouse embryonic fibroblast cell invasion. Oncogene 23:5577–5585",
      "volume": "23",
      "year": "2004"
    },
    {
      "DOI": "10.1158/1535-7163.MCT-09-0463",
      "author": "H Hirai",
      "doi-asserted-by": "crossref",
      "first-page": "2992",
      "journal-title": "Mol Cancer Ther",
      "key": "900_CR23",
      "unstructured": "Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, Itadani H, Takahashi-Suzuki I, Fukasawa K, Oki H, Nambu T, Jiang J, Sakai T, Arakawa H, Sakamoto T, Sagara T, Yoshizumi T, Mizuarai S, Kotani H (2009) Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol Cancer Ther 8:2992–3000",
      "volume": "8",
      "year": "2009"
    },
    {
      "DOI": "10.1038/nrclinonc.2010.64",
      "author": "F Janku",
      "doi-asserted-by": "crossref",
      "first-page": "401",
      "journal-title": "Nat Rev Clin Oncol",
      "key": "900_CR24",
      "unstructured": "Janku F, Stewart DJ, Kurzrock R (2010) Targeted therapy in non-small-cell lung cancer—is it becoming a reality? Nat Rev Clin Oncol 7:401–414",
      "volume": "7",
      "year": "2010"
    },
    {
      "DOI": "10.1101/gad.1815309",
      "author": "H Jiang",
      "doi-asserted-by": "crossref",
      "first-page": "1895",
      "journal-title": "Genes Dev",
      "key": "900_CR25",
      "unstructured": "Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT (2009) The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 23:1895–1909",
      "volume": "23",
      "year": "2009"
    },
    {
      "author": "JS Kim",
      "first-page": "2744",
      "journal-title": "Cancer Res",
      "key": "900_CR26",
      "unstructured": "Kim JS, Crooks H, Dracheva T, Nishanian TG, Singh B, Jen J, Waldman T (2002) Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res 62:2744–2748",
      "volume": "62",
      "year": "2002"
    },
    {
      "DOI": "10.1038/nrc1892",
      "author": "R Kumar",
      "doi-asserted-by": "crossref",
      "first-page": "459",
      "journal-title": "Nat Rev Cancer",
      "key": "900_CR27",
      "unstructured": "Kumar R, Gururaj AE, Barnes CJ (2006) p21-activated kinases in cancer. Nat Rev Cancer 6:459–471",
      "volume": "6",
      "year": "2006"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-04-1767",
      "author": "C Lee",
      "doi-asserted-by": "crossref",
      "first-page": "6906",
      "journal-title": "Cancer Res",
      "key": "900_CR28",
      "unstructured": "Lee C, Kim JS, Waldman T (2004) PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells. Cancer Res 64:6906–6914",
      "volume": "64",
      "year": "2004"
    },
    {
      "DOI": "10.1158/1535-7163.MCT-09-1027",
      "author": "DA Löser",
      "doi-asserted-by": "crossref",
      "first-page": "1775",
      "journal-title": "Mol Cancer Ther",
      "key": "900_CR29",
      "unstructured": "Löser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ (2010) Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 9:1775–1787",
      "volume": "9",
      "year": "2010"
    },
    {
      "DOI": "10.1016/0092-8674(91)90266-2",
      "author": "K Lundgren",
      "doi-asserted-by": "crossref",
      "first-page": "1111",
      "journal-title": "Cell",
      "key": "900_CR30",
      "unstructured": "Lundgren K, Walworth N, Booher R, Dembski M, Kirschner M, Beach D (1991) mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. Cell 64:1111–1122",
      "volume": "64",
      "year": "1991"
    },
    {
      "DOI": "10.1016/j.cell.2009.05.006",
      "author": "J Luo",
      "doi-asserted-by": "crossref",
      "first-page": "835",
      "journal-title": "Cell",
      "key": "900_CR31",
      "unstructured": "Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137:835–848",
      "volume": "137",
      "year": "2009"
    },
    {
      "DOI": "10.1056/NEJMoa0909530",
      "author": "M Maemondo",
      "doi-asserted-by": "crossref",
      "first-page": "2380",
      "journal-title": "N Engl J Med",
      "key": "900_CR32",
      "unstructured": "Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) North-East Japan Study Group Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388",
      "volume": "362",
      "year": "2010"
    },
    {
      "DOI": "10.1074/jbc.270.42.25070",
      "author": "E Manser",
      "doi-asserted-by": "crossref",
      "first-page": "25070",
      "journal-title": "J Biol Chem",
      "key": "900_CR33",
      "unstructured": "Manser E, Chong C, Zhao ZS, Leung T, Michael G, Hall C, Lim L (1995) Molecular cloning of a new member of the p21-Cdc42/Rac-activated kinase (PAK) family. J Biol Chem 270:25070–25078",
      "volume": "270",
      "year": "1995"
    },
    {
      "DOI": "10.4161/cbt.8.23.10271",
      "author": "H Michiue",
      "doi-asserted-by": "crossref",
      "first-page": "2306",
      "journal-title": "Cancer Biol Ther",
      "key": "900_CR34",
      "unstructured": "Michiue H, Eguchi A, Scadeng M, Dowdy SF (2009) Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol Ther 8:2306–2313",
      "volume": "8",
      "year": "2009"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-05-4629",
      "author": "S Mizuarai",
      "doi-asserted-by": "crossref",
      "first-page": "6319",
      "journal-title": "Cancer Res",
      "key": "900_CR35",
      "unstructured": "Mizuarai S, Yamanaka K, Kotani H (2006) Mutant p53 induces the GEF-H1 onogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res 66:6319–6326",
      "volume": "66",
      "year": "2006"
    },
    {
      "DOI": "10.2174/156652408786733676",
      "author": "S Mizuarai",
      "doi-asserted-by": "crossref",
      "first-page": "774",
      "journal-title": "Curr Mol Med",
      "key": "900_CR36",
      "unstructured": "Mizuarai S, Irie H, Schmatz DM, Kotani H (2008) Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets. Curr Mol Med 8:774–783",
      "volume": "8",
      "year": "2008"
    },
    {
      "DOI": "10.1186/1476-4598-8-34",
      "author": "S Mizuarai",
      "doi-asserted-by": "crossref",
      "first-page": "34",
      "journal-title": "Mol Cancer",
      "key": "900_CR37",
      "unstructured": "Mizuarai S, Yamanaka K, Itadani H, Arai T, Nishibata T, Hirai H, Kotani H (2009) Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor. Mol Cancer 8:34",
      "volume": "8",
      "year": "2009"
    },
    {
      "DOI": "10.1056/NEJMoa0810699",
      "author": "TS Mok",
      "doi-asserted-by": "crossref",
      "first-page": "947",
      "journal-title": "N Engl J Med",
      "key": "900_CR38",
      "unstructured": "Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957",
      "volume": "361",
      "year": "2009"
    },
    {
      "DOI": "10.1517/13543784.15.6.709",
      "author": "F Morgillo",
      "doi-asserted-by": "crossref",
      "first-page": "709",
      "journal-title": "Expert Opin Investig Drugs",
      "key": "900_CR39",
      "unstructured": "Morgillo F, Lee HY (2006) Lonafarnib in cancer therapy. Expert Opin Investig Drugs 15:709–719",
      "volume": "15",
      "year": "2006"
    },
    {
      "DOI": "10.1073/pnas.171076798",
      "author": "MS Neshat",
      "doi-asserted-by": "crossref",
      "first-page": "10314",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "900_CR40",
      "unstructured": "Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98:10314–10319",
      "volume": "98",
      "year": "2001"
    },
    {
      "DOI": "10.1007/s12094-008-0207-8",
      "author": "A Peralta-Leal",
      "doi-asserted-by": "crossref",
      "first-page": "318",
      "journal-title": "Clin Transl Oncol",
      "key": "900_CR41",
      "unstructured": "Peralta-Leal A, Rodríguez MI, Oliver FJ (2008) Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment. Clin Transl Oncol 10:318–323",
      "volume": "10",
      "year": "2008"
    },
    {
      "DOI": "10.1016/j.ccr.2010.05.025",
      "author": "M Puyol",
      "doi-asserted-by": "crossref",
      "first-page": "63",
      "journal-title": "Cancer Cell",
      "key": "900_CR42",
      "unstructured": "Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, Guerra C, Santamaría D, Barbacid M (2010) A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18:63–73",
      "volume": "18",
      "year": "2010"
    },
    {
      "DOI": "10.1016/j.ccr.2006.11.024",
      "author": "HC Reinhardt",
      "doi-asserted-by": "crossref",
      "first-page": "175",
      "journal-title": "Cancer Cell",
      "key": "900_CR43",
      "unstructured": "Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11:175–189",
      "volume": "11",
      "year": "2007"
    },
    {
      "DOI": "10.1038/356353a0",
      "author": "R Rowley",
      "doi-asserted-by": "crossref",
      "first-page": "353",
      "journal-title": "Nature",
      "key": "900_CR44",
      "unstructured": "Rowley R, Hudson J, Young PG (1992) The wee1 protein kinase is required for radiation-induced mitotic delay. Nature 356:353–355",
      "volume": "356",
      "year": "1992"
    },
    {
      "DOI": "10.1101/gad.979102",
      "author": "A Sainsbury",
      "doi-asserted-by": "crossref",
      "first-page": "1077",
      "issue": "9",
      "journal-title": "Genes Dev",
      "key": "900_CR45",
      "unstructured": "Sainsbury A, Schwarzer C, Couzens M, Jenkins A, Oakes SR, Ormandy CJ, Herzog H (2002) Y4 receptor knockout rescues fertility in ob/ob mice. Genes Dev 16(9):1077–1088",
      "volume": "16",
      "year": "2002"
    },
    {
      "DOI": "10.1080/07357900802087275",
      "author": "N Saxena",
      "doi-asserted-by": "crossref",
      "first-page": "948",
      "journal-title": "Cancer Invest",
      "key": "900_CR46",
      "unstructured": "Saxena N, Lahiri SS, Hambarde S, Tripathi RP (2008) RAS: target for cancer therapy. Cancer Invest 26:948–955",
      "volume": "26",
      "year": "2008"
    },
    {
      "DOI": "10.1126/science.1149200",
      "author": "MR Schlabach",
      "doi-asserted-by": "crossref",
      "first-page": "620",
      "journal-title": "Science",
      "key": "900_CR47",
      "unstructured": "Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, Zhao Z, Smogorzewska A, Sowa ME, Ang XL, Westbrook TF, Liang AC, Chang K, Hackett JA, Harper JW, Hannon GJ, Elledge SJ (2008) Cancer proliferation gene discovery through functional genomics. Science 319:620–624",
      "volume": "319",
      "year": "2008"
    },
    {
      "DOI": "10.1016/j.cell.2009.03.017",
      "author": "C Scholl",
      "doi-asserted-by": "crossref",
      "first-page": "821",
      "journal-title": "Cell",
      "key": "900_CR48",
      "unstructured": "Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG (2009) Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137:821–834",
      "volume": "137",
      "year": "2009"
    },
    {
      "author": "Y Shi",
      "first-page": "5027",
      "journal-title": "Cancer Res",
      "key": "900_CR49",
      "unstructured": "Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, Lichtenstein A (2002) Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62:5027–5034",
      "volume": "62",
      "year": "2002"
    },
    {
      "DOI": "10.4161/cc.8.23.10070",
      "author": "B Shor",
      "doi-asserted-by": "crossref",
      "first-page": "3831",
      "journal-title": "Cell Cycle",
      "key": "900_CR50",
      "unstructured": "Shor B, Gibbons JJ, Abraham RT, Yu K (2009) Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 8:3831–3837",
      "volume": "8",
      "year": "2009"
    },
    {
      "DOI": "10.1038/ng1650",
      "author": "JM Silva",
      "doi-asserted-by": "crossref",
      "first-page": "1281",
      "journal-title": "Nat Genet",
      "key": "900_CR51",
      "unstructured": "Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ, Siolas D, Hu G, Paddison PJ, Schlabach MR, Sheth N, Bradshaw J, Burchard J, Kulkarni A, Cavet G, Sachidanandam R, McCombie WR, Cleary MA, Elledge SJ, Hannon GJ (2005) Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 37:1281–1288",
      "volume": "37",
      "year": "2005"
    },
    {
      "author": "KS Smalley",
      "first-page": "699",
      "journal-title": "Curr Opin Investig Drugs",
      "key": "900_CR52",
      "unstructured": "Smalley KS (2010) PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Investig Drugs 11:699–706",
      "volume": "11",
      "year": "2010"
    },
    {
      "DOI": "10.1038/nature04304",
      "author": "DB Solit",
      "doi-asserted-by": "crossref",
      "first-page": "358",
      "journal-title": "Nature",
      "key": "900_CR53",
      "unstructured": "Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358–362",
      "volume": "439",
      "year": "2006"
    },
    {
      "DOI": "10.1038/300143a0",
      "author": "CJ Tabin",
      "doi-asserted-by": "crossref",
      "first-page": "143",
      "journal-title": "Nature",
      "key": "900_CR54",
      "unstructured": "Tabin CJ, Bradley SM, Bargmann CI, Weinberg RA, Papageorge AG, Scolnick EM, Dhar R, Lowy DR, Chang EH (1982) Mechanism of activation of a human oncogene. Nature 300:143–149",
      "volume": "300",
      "year": "1982"
    },
    {
      "DOI": "10.1038/nbt1001-940",
      "author": "CJ Torrance",
      "doi-asserted-by": "crossref",
      "first-page": "940",
      "journal-title": "Nat Biotechnol",
      "key": "900_CR55",
      "unstructured": "Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW (2001) Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat Biotechnol 19:940–945",
      "volume": "19",
      "year": "2001"
    },
    {
      "DOI": "10.1073/pnas.0711741105",
      "author": "J Tsai",
      "doi-asserted-by": "crossref",
      "first-page": "3041",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "900_CR56",
      "unstructured": "Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105:3041–3046",
      "volume": "105",
      "year": "2008"
    },
    {
      "DOI": "10.1016/S0140-6736(10)60892-6",
      "author": "A Tutt",
      "doi-asserted-by": "crossref",
      "first-page": "235",
      "journal-title": "Lancet",
      "key": "900_CR57",
      "unstructured": "Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235–244",
      "volume": "376",
      "year": "2010"
    },
    {
      "DOI": "10.1056/NEJMoa0805019",
      "author": "E Cutsem Van",
      "doi-asserted-by": "crossref",
      "first-page": "1408",
      "journal-title": "N Engl J Med",
      "key": "900_CR58",
      "unstructured": "Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417",
      "volume": "360",
      "year": "2009"
    },
    {
      "DOI": "10.4161/cbt.3.3.697",
      "author": "Y Wang",
      "doi-asserted-by": "crossref",
      "first-page": "305",
      "journal-title": "Cancer Biol Ther",
      "key": "900_CR59",
      "unstructured": "Wang Y, Decker SJ, Sebolt-Leopold J (2004) Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 3:305–313",
      "volume": "3",
      "year": "2004"
    },
    {
      "DOI": "10.1182/blood-2010-01-265769",
      "doi-asserted-by": "crossref",
      "key": "900_CR60",
      "unstructured": "Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T (2010) The PARP inhibitor olaparib induces significant killing of ATM deficient lymphoid tumour cells in vitro and in vivo. Blood [Epub ahead of print]"
    }
  ],
  "reference-count": 60,
  "references-count": 60,
  "resource": {
    "primary": {
      "URL": "http://link.springer.com/10.1007/s00439-010-0900-x"
    }
  },
  "score": 0,
  "short-container-title": [
    "Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements"
  ],
  "type": "journal-article",
  "volume": "128"
}